The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Palbociclib (P) in patients (pts) with soft tissue sarcoma (STS) with CDK4 amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
 
Scott Schuetze
Research Funding - Adaptimmune (Inst); Amgen (Inst); Blueprint Medicines (Inst); GlaxoSmithKline (Inst); Karyopharm Therapeutics (Inst)
Travel, Accommodations, Expenses - Blueprint Medicines
 
Michael Rothe
Research Funding - Eisai; Pfizer
 
Pam K. Mangat
No Relationships to Disclose
 
Liz Garrett-Mayer
Consulting or Advisory Role - Deciphera; TYME
 
Funda Meric-Bernstam
Employment - MD Anderson Cancer Center
Honoraria - Mayo Clinic; Rutgers Cancer Institute of New Jersey
Consulting or Advisory Role - Aduro Biotech; Alkermes; Debiopharm Group; eFFECTOR Therapeutics; Genentech; IBM; Immunomedics; Inflection Biosciences; Jackson Laboratory for Genomic Medicine; Kolon Life Sciences; Mersana; Origimed; PACT Pharma; Parexel International; Pfizer; Puma Biotechnology; Roche; Samsung Bioepis; Seagen; Silverback Therapeutics; Spectrum Pharmaceuticals; Tyra Biosciences; Xencor; Zentalis; Zymeworks
Speakers' Bureau - Chugai Pharma
Research Funding - Abbvie (Inst); Aileron Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (I); Calithera Biosciences (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); eFFECTOR Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Guardant Health (Inst); Jounce Therapeutics (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); PUMA Biotechnology (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Beth Israel Deaconess Medical Center; Taiho Pharmaceutical
 
Laura Catherine Farrington
Employment - Cancer Treament Centers of America
 
Carmen Calfa
No Relationships to Disclose
 
Stacy D. D'Andre
No Relationships to Disclose
 
Michael B. Livingston
No Relationships to Disclose
 
Ramya Thota
No Relationships to Disclose
 
Alissa S. Marr
No Relationships to Disclose
 
Margaret von Mehren
Consulting or Advisory Role - deciphera; Exelixis
Research Funding - Arog (Inst); ArQule; ASCO (Inst); Blueprint Medicines (Inst); Deciphera (Inst); Genmab (Inst); Gradalis (Inst); Lilly (Inst); Novartis (Inst); Springworks Therapeutics (Inst)
Travel, Accommodations, Expenses - Deciphera; NCCN
Other Relationship - NCCN
 
Kristopher Wentzel
No Relationships to Disclose
 
Richard L. Schilsky
Consulting or Advisory Role - Cellworks; Scandion Oncology
Research Funding - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst)